Biotech News
TCA Venture Group highlights for 2025 include four exits, led by 44x return from ParentSquare, investment in 43 companies, and successful annual chapter funds that add diversification and capital
Commercial Launch Announcement Marks a New Chapter for NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP) — FDA-Approved Preservative-Free Ketamine Now Being Sold, 17-Person National Sales Team Activated, Market Relationships Cover Approximately 80% of U.S. Ke
The new treatment option is being introduced through OncoBeta's partnership with Greek medical technology company, Mediray
Genprex, Inc. (N A S D A Q: GNPX) Provides New Clinical Patient Analysis Uncovers Promising TUSC2-Associated Biological Activity Involving Mitochondrial Function, Cellular Repair, Autophagy and Protein Quality Control. Combined With the Roche Diagnostics
Strategic Roche Diagnostics Partnership, New Biomarker Findings and Expanding Clinical Research Could Help Transform Patient Selection for Non-Small Cell Lung Cancer Treatment, While Genprex, Inc. (N A S D A Q: GNPX) Advances Additional Opportunities in S
NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP) $NRXP Also Received an $11 Million Dollar Award for Robotic Magnetic Stimulation with Pharma Treatment for Resistant Depression
A Landmark October 30th FDA Approval, Commercial Manufacturing Readiness, Two-Year Stability Results, and an $11.25 Million DARPA Research Contract Put NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP) at an Important Turning Point in Its Growth
Roche Diagnostics $RHHBY Collaboration, Promising REQORSA® Biomarker Research, and Expanding Gene Therapy Programs Put Genprex $GNPX in the Spotlight
$SNNC acquires Majority Stake in New Joint Venture With Doc-Rx Opens the Door to Telehealth, U.S.-Made Peptides and an Ambitious Wellness Clinic Expansion Strategy
NRXP Reports Three Successfully Manufactured Commercial Lots, Two-Year Stability Data, and Commercially Releasable Supply Pending FDA Approval — While an $11.18 Million DARPA Contract Expands the Company's Research Opportunities
October 15 FDA Update Confirms Minor Labeling Changes Ahead of November 10 Goal Date, While an $11.18 Million DARPA Contract and Innovative Depression Research Expand the Company's Potential
USPTO allows 26 claims for ophthalmic formulations containing quaternary chitosan derivatives, marking a key step toward U.S. patent protection.
Founded by a former biotech finance professional, biosuite helps smaller biotech teams track financial commitments to research partners before the corresponding invoices arrive.
Today's landmark defense contract launches the FDA-approved SPARC-TMS trial while NRx simultaneously advances its preservative-free ketamine program, HOPE Therapeutics and an expanding CNS pipeline
As fentanyl continues to drive an enormous public-health challenge in the United States, Nutriband's AVERSA™ technology is being developed to address a different but important piece of the problem: abuse, misuse, diversion and accidental exposure involvin
Some deaths in Utah never come under the authority of the state Office of the Medical Examiner, which leaves families without a postmortem examination.
$NTRB reaches a new 52-week high of $9.00 and closes at $8.99, extending a powerful September advance as the company approaches the September 30 expiration of 910,904 publicly traded warrants and continues advancing its AVERSA™ abuse-deterrent transdermal
Strategic agreement expands bioprocessing equipment (SFC systems) availability to the Pharma industry across Europe after Novasep exited the technology years ago.
From equations and experiments in the laboratory to exclusive skincare for skin longevity
Competitive National Eye Institute funding provides external validation of ClearSight's proposed scientific program and supports a one-year investigation of a preservative-free ophthalmic formulation in acute infectious conjunctivitis and epidemic keratoc
New worldwide agreement adds human cellular validation to Lunai's AI-driven Parkinson's platform, creating a potential path from patient subtypes and biomarkers to biological mechanisms and therapeutic targets. Positioned for $400M to $1.2 Billion US Coun